Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Alphs

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Perspectives in Psychiatric Care|February 16, 2018
An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitateJennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, et al.
Schizophrenia Research|August 2, 2003
The InterSePT scale for suicidal thinking reliability and validityJ P Lindenmayer, Pal Czobor, Larry Alphs, et al.
The Journal of Clinical Psychiatry|May 5, 2015
Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month studyLarry Alphs, Carmela Benson, Kimberly Cheshire-Kinney, et al.
Innovations in Clinical Neuroscience|December 2, 2011
Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorderNorris Turner, Wayne Macfadden, Ravi Anand, et al.
Applied Health Economics and Health Policy|April 24, 2014
Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorderSudeep Karve, Michael Markowitz, Dong-Jing Fu, et al.
Psychiatric Services (Washington, D.C.)|March 17, 2015
Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia TreatmentBennett Levitan, Michael Markowitz, Ateesha F Mohamed, et al.
Journal of Clinical Psychopharmacology|June 21, 2016
Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective DisorderDong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.
Biological Psychiatry|August 14, 2003
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trialSteven G Potkin, Larry Alphs, Chuanchieh Hsu, et al.
Psychiatric Services (Washington, D.C.)|May 16, 2014
Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatmentMichael A Markowitz, Bennett S Levitan, Ateesha F Mohamed, et al.
Pharmaceutical Statistics|January 24, 2007
A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressantCraig Mallinckrodt, Christy Chuang-Stein, Paul McSorley, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Perspectives in Psychiatric Care|February 16, 2018
An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitateJennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, et al.
Schizophrenia Research|August 2, 2003
The InterSePT scale for suicidal thinking reliability and validityJ P Lindenmayer, Pal Czobor, Larry Alphs, et al.
The Journal of Clinical Psychiatry|May 5, 2015
Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month studyLarry Alphs, Carmela Benson, Kimberly Cheshire-Kinney, et al.
Innovations in Clinical Neuroscience|December 2, 2011
Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorderNorris Turner, Wayne Macfadden, Ravi Anand, et al.
Applied Health Economics and Health Policy|April 24, 2014
Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorderSudeep Karve, Michael Markowitz, Dong-Jing Fu, et al.
Psychiatric Services (Washington, D.C.)|March 17, 2015
Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia TreatmentBennett Levitan, Michael Markowitz, Ateesha F Mohamed, et al.
Journal of Clinical Psychopharmacology|June 21, 2016
Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective DisorderDong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.
Biological Psychiatry|August 14, 2003
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trialSteven G Potkin, Larry Alphs, Chuanchieh Hsu, et al.
Psychiatric Services (Washington, D.C.)|May 16, 2014
Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatmentMichael A Markowitz, Bennett S Levitan, Ateesha F Mohamed, et al.
Pharmaceutical Statistics|January 24, 2007
A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressantCraig Mallinckrodt, Christy Chuang-Stein, Paul McSorley, et al.
Pageof 12